FDA Inspection
Kite Pharma, Inc.Kite Pharma, Inc. – FDA Inspection, Jun 16, 2017
Record Details
This FDA Inspection record concerns Kite Pharma, Inc., with an inspection on June 16, 2017, issued by the Los Angeles District Office, covering biologics.
- People
- Arie Menachem (Issuing Officer)
- Donald B. Ertel (Issuing Officer)
- Graeme E. Price
- Michael B. Havert (Issuing Officer)
- Wei Wang (Company Rep)
View Company Profile
ID · edd81dfc-f202-4cbe-8592-4d5b2bf6e545
Inspection Facts
- Inspection number
- 1015808
- FDA center
- Biologics
- Outcome
- Form 483 issued
Other FDA inspections of Kite Pharma, Inc.
3| Date | Classification | Office | Project area |
|---|---|---|---|
| August 27, 2025 | VAI | Los Angeles District Office | Human Cellular, Tissue, and Gene Therapies |
| October 22, 2021 | VAI | Center for Biologics Evaluation and Research | Human Cellular, Tissue, and Gene Therapies |
| August 20, 2019 | VAI | Center for Biologics Evaluation and Research | Human Cellular, Tissue, and Gene Therapies |
Other documents for Kite Pharma, Inc.
- FDA Inspection 1279894 - 2025-08-27
- FDA Inspection 1155166 - 2021-10-22
- FDA Inspection 1100058 - 2019-08-20
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.